- Home
- RDIB vs ABOS Comparison
RDIB vs ABOS Comparison
Compare RDIB & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RDIB | ABOS |
|---|---|---|
| Founded | 1937 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 204.5M | 197.9M |
| IPO Year | 1994 | 2021 |
Fundamental Metrics
Financial Performance| Metric | RDIB | ABOS |
|---|---|---|
| Price | $19.88 | $2.92 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | ★ 399.0K | 340.2K |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 60.76 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $202,988,000.00 | N/A |
| Revenue This Year | $16.25 | N/A |
| Revenue Next Year | $4.04 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.01 | $1.21 |
| 52 Week High | $17.77 | $3.60 |
Technical Indicators
Market Signals| Indicator | RDIB | ABOS |
|---|---|---|
| Relative Strength Index (RSI) | 75.08 | 61.79 |
| Support Level | $10.47 | $2.13 |
| Resistance Level | $17.40 | $3.02 |
| Average True Range (ATR) | 0.84 | 0.18 |
| MACD | 0.80 | 0.03 |
| Stochastic Oscillator | 72.95 | 58.75 |
Price Performance
Historical ComparisonAbout RDIB Reading International Inc Class B
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.